JP2003081849A - Aldose reductase inhibitor - Google Patents

Aldose reductase inhibitor

Info

Publication number
JP2003081849A
JP2003081849A JP2001279413A JP2001279413A JP2003081849A JP 2003081849 A JP2003081849 A JP 2003081849A JP 2001279413 A JP2001279413 A JP 2001279413A JP 2001279413 A JP2001279413 A JP 2001279413A JP 2003081849 A JP2003081849 A JP 2003081849A
Authority
JP
Japan
Prior art keywords
leaves
aldose reductase
leaf
production example
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001279413A
Other languages
Japanese (ja)
Other versions
JP4818549B2 (en
Inventor
Keiji Takagi
啓二 高木
Kenji Shimomura
健次 下村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mikimoto Pharmaceutical Co Ltd
Original Assignee
Mikimoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikimoto Pharmaceutical Co Ltd filed Critical Mikimoto Pharmaceutical Co Ltd
Priority to JP2001279413A priority Critical patent/JP4818549B2/en
Publication of JP2003081849A publication Critical patent/JP2003081849A/en
Application granted granted Critical
Publication of JP4818549B2 publication Critical patent/JP4818549B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide an aldose reductase inhibitor derived from a plant, for preventing various kinds of complication of diabetes. SOLUTION: This aldose reductase inhibitor is obtained by formulating one or more kinds of extracts of leaves of Fragaria vesca or the like, Salvia officinalis or the like, Tamarix chinensis Lour, Agrimonia pilosa, leaves of Mimusops elengi, leaves of Anthriscus cerefolium, leaves of Allium schoenoprasum, and Rheum Palmatum Linne or the like. The components of the inhibitor is a plant eaten as a food up to now and has the high safety, and the inhibitor can inhibit the aldose reductase, and prevent the various kinds of the complication of the diabetes.

Description

【発明の詳細な説明】 【0001】 【産業上の利用分野】本発明は糖尿病の各種の合併症を
防ぐアルドースレダクターゼ阻害剤に関する。 【0002】 【従来の技術】我が国では約600万人もの糖尿病患者
がおり、さらにその傾向がある人も含めればわが国の人
口の10%にも達し、国民病の規模になりつつある。糖
尿病には、インシュリン依存型とインシュリン非依存型
との2つのタイプがあり、日本人の患者のほとんどがイ
ンシュリン非依存性糖尿病である。しかし、糖尿病は各
種の合併症を引き起こすと言われている。 【0003】ストロベリーリーフはイチゴ(Fragaria v
esca,F. viridis,F. mosahata,F. chiloensis,F. virgi
niana)の葉であり、茶として飲用されている。 【0004】セージ(Salvia officinalis S. lavandul
aefolia S. tribolaulmaria)は地中海原産の植物でヨ
ーロッパに広く分布し、葉は薬用として、消炎、収斂の
目的で利用されてまた、香辛料としても広く利用されて
いる。 【0005】西河柳はギョリュウ科ギョリュウ属の学名
をタマリックス チネンシス ロウア(Tamarix chinensi
s Lour)、通称ギョリュウと呼ばれる植物の葉のついた
若枝である。この植物は原産は中国であるが、鑑賞用と
して日本に渡来し、庭等に植えられている落葉小高木で
ある。用途としては、発汗、解熱、利尿、鎮咳、抗菌
(肺炎球菌、α−レンサ球菌、白色ブドウ球菌、インフ
ルエンザ)として用いられている。 【0006】仙鶴草はその全草を利用されている。その
目的は止血、止瀉、消炎、強壮薬として、吐血、便血、
尿血、崩漏帯下、赤白痢疾等の諸出血症状に利用されて
いる。しかし化粧料としては特開平1−313414号
で頭部化粧料として、特開昭60−184024号で殺
菌性組成物として利用されているにすぎない。 【0007】ミムソプス エレンギ(Mimusops elengi)
はインドからネパールのタライ地方に産する。アカテツ
科の常緑の小高木で、ミサキノハナと称し庭木としても
よく植えられている。樹皮は暗灰色で亀裂がある。葉は
楕円形〜長楕円形で花は腋性で単生、または束生で小さ
く淡黄色で星形をしており、香りがよい。薬品的な利用
は樹皮は収斂性で強壮剤となり、また熱にも処方され
る。葉は蛇に咬まれたときの治療にも使われる。 【0008】チャービル(Anthriscus cerefolium)の
葉は中東・東ロシア、コーカサス原産でフランスで広く
用いられている。用途は健胃薬である。 【0009】チャイブス(Allium schoenoprasum)(別
名アサツキ)の葉はヨーロッパやアメリカに分布し、料
理に用いられている。 【0010】大黄は古くより、内用薬として用いられ、
水製、或いはエタノールエキスが用いられ、その安全性
は充分に確認されている。大黄には、いろいろな種類の
植物が使われている。ショウヨウダイオウ(Rheum Palm
atum Linne)、タングートダイオウ(Rheum tanguticum
Maximowicz )、ダイオウ(Rheum officinale Baillo
n)、チョウセンダイオウ(Rheum coreanum Nakai)ま
たはそれらの種間雑種、例えば信州大黄等がある。これ
らの植物の根茎をもちいたのが大黄である。 【0011】 【従来の技術および発明が解決しようとする課題】イン
シュリン非依存的に、グルコースの取り込みを行う水晶
体、網膜、末梢神経などの組織では、糖尿病による高い
血糖値により細胞内グルコース濃度が上昇し、主経路の
解糖系で代謝しきれない過剰のグルコースは、細胞中の
アルドースレダクターゼによりソルビトールに変換され
る。ソルビトールは細胞膜電荷のために細胞外に出にく
く、さらにソルビトール脱水酵素(副経路のポリオール
経路上でフルクトースへの変換を促す)による処理速度
が遅いことなどから、ソルビトールが細胞内に蓄積さ
れ、細胞内浸透圧が上昇して細胞の膨化と細胞膜の変性
が起こり、結果としておきた細胞障害により、網膜症、
腎症、神経障害等の糖尿病合併症等の種々の糖尿病合併
症が発症すると考えられている。従来、糖尿病の治療薬
として、インシュリンや種々の血糖降下剤が用いるのみ
ならず、糖尿病合併症に関しても充分な注意が必要であ
るので、これに関与するアルドースレダクターゼの活性
を阻害する物質を配合することによってさらに有効な薬
品あるいは食品を得ることを目的とした。 【0012】 【課題を解決するための手段】本発明者らは安全で有効
なアルドースレダクターゼ阻害活性成分について種々検
討した結果、ストロベリーリーフ、セージ、西河柳、仙
鶴草、ミサキノハナの葉、チャービルの葉、チャイブス
の葉、大黄の1種以上の抽出物が高い阻害活性を有する
ことを見出し、本発明に到達した。 【0013】これらの植物を水或いは水溶性有機溶媒或
いは、水溶性有機溶媒と水の混合物で抽出する。水溶性
有機溶媒はメタノール、エタノール、グリセリン、プロ
ピレングリコール、或いはこれらの混合物を用いること
ができる。熱を加えることも抽出速度が増すので必要に
よりこの工程を加える。 【0014】このように抽出したストロベリーリーフ、
セージ、西河柳、仙鶴草、ミサキノハナの葉、チャービ
ルの葉、チャイブスの葉、大黄の抽出物を必要により溶
媒を留去して、薬や食品にさまざまな剤型に配合するこ
とができる。例えば、丸薬、錠剤、シロップ、粉末、健
康茶の形態にすることができる。 【0015】また、本発明は糖尿病の合併症予防のため
用いられるものなので、当然、スルホニル尿素剤、スル
ホンアミド薬、ビグアナイド薬、ボグリボース、アカル
ボースなどの糖尿病予防薬やヤーコン、ギムネバシルベ
スタ、シベリア人参、高麗人参、プロポリス、ビージャ
サーラなどの糖尿病予防を予防する食品との併用するこ
とが好ましく、この薬或いは食品にも同時に血糖降下剤
などの糖尿病予防に有効な成分を配合することが望まし
い。また、所謂,食事療法も併用することが望ましい。 【0016】 【実施例】以下に製造例、実施例によって、更に具体的
に説明するが、本発明は、この製造例、実施例によっ
て、限定されるものでないことは云うまでもない。 【0017】〔製造例1〕ストロベリーリーフ(Fragar
ia vescaの葉)(乾燥品)10gを細砕したのち、精製
水300mlを加えて時々撹拌しつつ5時間、加熱した。
これを放冷したのち、濾過し、凍結乾燥した。 【0018】〔製造例2〕セージ(Salvia officinalis
の葉)(乾燥品)10gを細砕したのち、50%エタノ
ール水溶液300mlを加えて時々撹拌しつつ5日間放置
した。これを濾過後、エバポレートした後、凍結乾燥し
た。 【0019】〔製造例3〕西河柳(乾燥品)10gを細
砕したのち、50%エタノール水溶液300mlを加えて
時々撹拌しつつ5日間放置した。これを濾過後、エバポ
レートした後、凍結乾燥した。 【0020】〔製造例4〕仙鶴草(乾燥品)10gを細
砕したのち、50%エタノール水溶液300mlを加えて
時々撹拌しつつ5日間放置した。これを濾過後、エバポ
レートした後、凍結乾燥した。 【0021】〔製造例5〕ミサキノハナの葉(乾燥品)
10gを細砕したのち、50%エタノール水溶液300
mlを加えて時々撹拌しつつ5日間放置した。これを濾過
後、エバポレートした後、凍結乾燥した。 【0022】〔製造例6−1〕チャービルの葉(乾燥
品)10gを細砕したのち、50%エタノール水溶液3
00mlを加えて時々撹拌しつつ5日間放置した。これを
濾過後、エバポレートした後、凍結乾燥した。 【0023】〔製造例6−2〕チャービルの葉(乾燥
品)10gを細砕したのち、精製水300mlを加えて時
々撹拌しつつ5時間、加熱した。これを放冷したのち、
濾過し、凍結乾燥した。 【0024】〔製造例7−1〕チャイブスの葉(乾燥
品)10gを細砕したのち、50%エタノール水溶液3
00mlを加えて時々撹拌しつつ5日間放置した。これを
濾過後、エバポレートした後、凍結乾燥した。 【0025】〔製造例7−2〕チャイブスの葉(乾燥
品)10gを細砕したのち、精製水300mlを加えて時
々撹拌しつつ5時間、加熱した。これを放冷したのち、
濾過し、凍結乾燥した。 【0026】〔製造例8〕大黄(Rheum officinale Bai
llon)(乾燥品)10gを細砕したのち、50%エタノ
ール水溶液300mlを加えて時々撹拌しつつ5日間放置
した。これを濾過後、エバポレートした後、凍結乾燥し
た。 【0027】実施例−1 健康食品(錠剤) A:ヤーコン 20.0% B:プロポリス 10.0% C:ビタミンE 5.0% D:製造例1 25.0% E:デキストリン 25.0% F:結晶セルロース 22.5% G:ショ糖脂肪酸エステル 2.0% H:デンプン 0.5% 製法はA〜Fの各成分を秤量し、流動層造粒機でHを結
合剤溶液として顆粒化する。その後Gを加え均一に混合
し打錠機で錠剤とする。 【0028】実施例−2 健康食品(顆粒) A:製造例2 20.0% B:製造例3 20.0% C:製造例4 10.0% D:エリスリトール 30.0% E:結晶セルロース 18.0% F:ショ糖脂肪酸エステル 1.5% G:デンプン 0.5% 製法はA〜Eの各成分を秤量し、流動層造粒機でGを結
合剤溶液として顆粒化する。その後Fを加え均一に混合
し顆粒とする。 【0029】実施例−3 スープ(粉末スープ) A:高麗人参 20.0% B:製造例5 10.0% C:製造例6−1 5.0% D:製造例6−2 5.0% E:大豆タンパク 15.0% F:粉末油脂 13.0% G:ブイヨン 11.0% H:食塩 6.0% I:増粘剤(グァーガム) 5.0% J:乳タンパク 5.0% K:調味料(アミノ酸等) 3.0% L:香料 2.0% 製法はA〜Lの各成分を秤量し均一に混合して粉末スー
プとする。 【0030】実施例−4 お茶(粉末タイプ) A:製造例7−2 10.0% B:製造例8 10.0% C:製造例1 10.0% D:バナバ茶 25.0% E:ハト麦 25.0% F:紅茶 20.0% 製法はA〜Fの各成分を秤量し均一に混合して粉末とす
る。 【0031】実施例−5 健康食品(錠剤) A:ギムネバシルベスタ 20.0% B:シベリア人参 10.0% C:ビタミンE 5.0% D:製造例2 15.0% D:製造例3 10.0% E:デキストリン 25.0% F:結晶セルロース 22.5% G:ショ糖脂肪酸エステル 2.0% H:デンプン 0.5% 製法はA〜Fの各成分を秤量し、流動層造粒機でHを結
合剤溶液として顆粒化する。その後Gを加え均一に混合
し打錠機で錠剤とする。 【0032】実施例−6 健康食品(顆粒) A:製造例4 20.0% B:製造例5 20.0% C:製造例6−1 10.0% D:エリスリトール 30.0% E:結晶セルロース 18.0% F:ショ糖脂肪酸エステル 1.5% G:デンプン 0.5% 製法はA〜Eの各成分を秤量し、流動層造粒機でGを結
合剤溶液として顆粒化する。その後Fを加え均一に混合
し顆粒とする。 【0033】アルドースレダクターゼ阻害試験 試験方法を以下に示す。水1.5ml、0.175%メルカ
プトエタノールを含む500mMリン酸カリウムバッフ
ァー(pH6.0)0.6ml、1Mグルコース水溶液0.
6ml、サンプル溶液0.05ml、2mMのNADPH水
溶液(pH7.0)0.15ml、0.035%メルカプト
エタノールを含む10mMリン酸ナトリウムバッファー
(pH7.0)3.6mlに1.3unit/mlのアルドースレ
ダクターゼ0.4mlを加えた溶液0.1mlを以上の順で混
合する。酵素添加と同時に時間を計る。37℃でインキ
ュベートしながら5分間340nmの吸光度を測定す
る。水を対照としたときの吸光度が経時的に低下するの
で、サンプルの1分間の吸光度低下の抑制率を酵素阻害
率とした。 【0034】結果を表に示す。【0035】 【効果】ストロベリーリーフ、セージ、西河柳、仙鶴
草、ミサキノハナの葉チャービルの葉、チャイブスの
葉、大黄の抽出物の1種以上の抽出物を配合したアルド
ースレダクターゼ阻害剤は今まで食用とされた植物で安
全性が高く、アルドースレダクターゼを阻害し、糖尿病
の各種の合併症を防ぐことができる。
Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an aldose reductase inhibitor for preventing various complications of diabetes. [0002] In Japan, there are about 6 million diabetic patients, including those who tend to have it, reaching 10% of Japan's population, and the scale of national illness is increasing. There are two types of diabetes, insulin-dependent and non-insulin-dependent, and most Japanese patients have non-insulin-dependent diabetes. However, diabetes is said to cause various complications. [0003] Strawberry leaf is a strawberry (Fragaria v
esca, F. viridis, F. mosahata, F. chiloensis, F. virgi
niana) leaf, which is consumed as tea. [0004] Sage (Salvia officinalis S. lavandul)
aefolia S. tribolaulmaria) is a plant native to the Mediterranean, widely distributed in Europe, and its leaves are widely used as medicinal, anti-inflammatory and astringent purposes, and also as spices. [0005] Nishikawayanagi has given the scientific name of the genus Goryoli in the family Goryoliaceae to Tamarix chinensis roua.
s Lour), a shoot with leaves on a plant commonly known as Gory リ ュ. Although this plant is native to China, it is a deciduous small tree that has been introduced to Japan for appreciation and is planted in gardens and the like. It is used as perspiration, antipyretic, diuretic, antitussive, antibacterial (pneumococci, α-streptococci, staphylococcus, influenza). [0006] The whole plant is used for Senkaku. Its purpose is hemostasis, antidiarrhea, anti-inflammatory, tonic,
It is used for various bleeding symptoms such as urinary blood, cramps, and dysentery. However, cosmetics are only used as head cosmetics in JP-A-1-313414 and as bactericidal compositions in JP-A-60-184024. [0007] Mimusops elengi
Comes from India in the Tarai region of Nepal. It is an evergreen small tree of the Acate family, and is often planted as a garden tree called Misaki Nohana. The bark is dark gray with cracks. The leaves are elliptical to oblong and the flowers are axillary and solitary, or bunchy, small, pale yellow, star-shaped, and fragrant. For chemical use, bark is astringent and tonic, and is also prescribed for heat. The leaves are also used to treat snake bites. [0008] The chervil (Anthriscus cerefolium) leaf is native to the Middle East and Eastern Russia and the Caucasus and is widely used in France. Use is as a stomachic. [0009] The leaves of chives (Allium schoenoprasum) (also known as Asatsuki) are distributed in Europe and the United States and are used in cooking. Rhubarb has been used as an internal medicine since ancient times,
Water or ethanol extract is used, and its safety has been sufficiently confirmed. Various types of plants are used in rhubarb. Rhinoceros (Rheum Palm)
atum Linne, Rheum tanguticum
Maximowicz, Rhubarb (Rheum officinale Baillo)
n), Rheum coreanum Nakai or their interspecific hybrids, such as Shinshu Daio. Rhubarb used rhizomes of these plants. [0011] In tissues such as the lens, retina, and peripheral nerves that take up glucose independently of insulin, the intracellular glucose concentration increases due to a high blood glucose level due to diabetes. However, excess glucose that cannot be completely metabolized by the glycolysis of the main pathway is converted to sorbitol by aldose reductase in cells. Sorbitol is difficult to get out of the cell due to cell membrane charge, and the processing speed by sorbitol dehydratase (promotes the conversion of fructose to fructose on the alternative pathway) is slow. Increased internal osmotic pressure causes swelling of cells and degeneration of cell membrane, resulting in cell damage, retinopathy,
It is considered that various diabetic complications such as diabetic complications such as nephropathy and neuropathy occur. Conventionally, as a therapeutic agent for diabetes, not only insulin and various hypoglycemic agents are used, but also sufficient attention is required regarding diabetic complications. Therefore, a substance that inhibits the activity of aldose reductase involved in this is compounded. Thus, the purpose was to obtain a more effective drug or food. Means for Solving the Problems The present inventors have conducted various studies on aldose reductase inhibitory active ingredients which are safe and effective. As a result, strawberry leaf, sage, Nishikawayanagi, sensurugusa, Misakinohana leaf, chervil leaf , Chives leaves, and one or more extracts of rhubarb have high inhibitory activity, and have reached the present invention. These plants are extracted with water or a water-soluble organic solvent or a mixture of a water-soluble organic solvent and water. As the water-soluble organic solvent, methanol, ethanol, glycerin, propylene glycol, or a mixture thereof can be used. Heating also increases the extraction rate, so this step is added if necessary. The strawberry leaf thus extracted,
Extracts of sage, Nishikawayanagi, Senkaku-so, Misakinohana leaf, chervil leaf, chives leaf, and rhubarb extract can be distilled off the solvent if necessary, and can be incorporated into medicines and foods in various dosage forms. For example, it can be in the form of pills, tablets, syrups, powders, and health tea. Since the present invention is used for the prevention of complications of diabetes, it should be understood that diabetes preventives such as sulfonylureas, sulfonamides, biguanides, voglibose and acarbose, yacon, gymneva sylvestre, siberian ginseng, etc. , Ginseng, propolis, villasala and the like, which are preferably used in combination with foods for preventing diabetes, and the medicine or the food is desirably combined with a component effective for preventing diabetes, such as a hypoglycemic agent. It is also desirable to use a so-called diet therapy together. EXAMPLES The present invention will be described more specifically with reference to production examples and examples, but it is needless to say that the present invention is not limited to these production examples and examples. [Production Example 1] Strawberry leaf (Fragar
After crushing 10 g of ia vesca leaf) (dried product), 300 ml of purified water was added, and the mixture was heated for 5 hours with occasional stirring.
After allowing to cool, it was filtered and freeze-dried. [Production Example 2] Sage (Salvia officinalis)
Leaves) (dried product) (10 g) was pulverized, and 300 ml of a 50% aqueous ethanol solution was added thereto, and the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. [Production Example 3] 10 g of Nishikawayanagi (dried product) was pulverized, and then 300 ml of a 50% aqueous ethanol solution was added. The mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. [Preparation Example 4] 10 g of dried sardines were ground, and 300 ml of a 50% aqueous ethanol solution was added. The mixture was allowed to stand for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. [Production Example 5] Misakinohana leaf (dried product)
After crushing 10 g, a 50% aqueous ethanol solution 300
ml was added and left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. [Production Example 6-1] After crushing 10 g of chervil leaves (dried product), a 50% aqueous ethanol solution 3
After adding 00 ml, the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. [Production Example 6-2] After crushing 10 g of chervil leaves (dried product), 300 ml of purified water was added, and the mixture was heated for 5 hours with occasional stirring. After letting it cool,
Filtered and lyophilized. [Production Example 7-1] After crushing 10 g of chives leaves (dried product), a 50% aqueous ethanol solution 3
After adding 00 ml, the mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. [Production Example 7-2] 10 g of chives leaves (dried product) was pulverized, and 300 ml of purified water was added thereto, followed by heating for 5 hours with occasional stirring. After letting it cool,
Filtered and lyophilized. [Production Example 8] Rhubarb (Rheum officinale Bai
llon) (dry product) (10 g) was pulverized, and 300 ml of a 50% aqueous ethanol solution was added thereto. The mixture was left for 5 days with occasional stirring. After filtration, evaporation and freeze-drying. Example-1 Health food (tablet) A: 20.0% of yacon B: 10.0% of propolis C: 5.0% of vitamin E D: Production example 1 25.0% E: Dextrin 25.0% F: crystalline cellulose 22.5% G: sucrose fatty acid ester 2.0% H: starch 0.5% The production method weighs each of the components A to F, and granulates H as a binder solution using a fluidized bed granulator. Become Thereafter, G is added and mixed uniformly to form tablets with a tableting machine. Example 2 Healthy Food (Granules) A: Production Example 2 20.0% B: Production Example 3 20.0% C: Production Example 4 10.0% D: Erythritol 30.0% E: Microcrystalline cellulose 18.0% F: Sucrose fatty acid ester 1.5% G: Starch 0.5% In the manufacturing method, each component of A to E is weighed, and G is granulated as a binder solution by a fluidized bed granulator. Thereafter, F is added and mixed uniformly to obtain granules. Example-3 Soup (powder soup) A: Ginseng 20.0% B: Production Example 5 10.0% C: Production Example 6-1 5.0% D: Production Example 6-2 5.0 % E: soy protein 15.0% F: powdered fat 13.0% G: bouillon 11.0% H: salt 6.0% I: thickener (guar gum) 5.0% J: milk protein 5.0 % K: Seasoning (amino acid etc.) 3.0% L: Flavor 2.0% In the manufacturing method, each component of A to L is weighed and uniformly mixed to make a powder soup. Example-4 Tea (powder type) A: Production Example 7-2 10.0% B: Production Example 8 10.0% C: Production Example 1 10.0% D: Banaba tea 25.0% E : Pigeon wheat 25.0% F: Black tea 20.0% In the manufacturing method, each component of A to F is weighed and uniformly mixed to obtain a powder. Example-5 Healthy Food (Tablets) A: Gymneva Sylvester 20.0% B: Siberian Ginseng 10.0% C: Vitamin E 5.0% D: Production Example 2 15.0% D: Production Example 3 10.0% E: Dextrin 25.0% F: Microcrystalline cellulose 22.5% G: Sucrose fatty acid ester 2.0% H: Starch 0.5% In the production method, each component of A to F is weighed and fluidized. Granulate H as a binder solution in a bed granulator. Thereafter, G is added and mixed uniformly to form tablets with a tableting machine. Example-6 Healthy Food (Granules) A: Production Example 4 20.0% B: Production Example 5 20.0% C: Production Example 6-1 10.0% D: Erythritol 30.0% E: Microcrystalline cellulose 18.0% F: Sucrose fatty acid ester 1.5% G: Starch 0.5% In the manufacturing method, each component of A to E is weighed, and G is granulated as a binder solution by a fluidized bed granulator. . Thereafter, F is added and mixed uniformly to obtain granules. Aldose reductase inhibition test The test method is described below. 1.5 ml of water, 0.6 ml of 500 mM potassium phosphate buffer (pH 6.0) containing 0.175% mercaptoethanol, and 0.1 ml of 1M aqueous glucose solution.
1.3 unit / ml aldose in 6 ml, 0.05 ml of sample solution, 0.15 ml of 2 mM NADPH aqueous solution (pH 7.0), and 3.6 ml of 10 mM sodium phosphate buffer (pH 7.0) containing 0.035% mercaptoethanol. 0.1 ml of a solution containing 0.4 ml of reductase is mixed in the above order. Time the addition of the enzyme. Measure the absorbance at 340 nm for 5 minutes while incubating at 37 ° C. Since the absorbance of water as a control decreases with time, the inhibition rate of the absorbance decrease of the sample for 1 minute was defined as the enzyme inhibition rate. The results are shown in the table. [Effect] An aldose reductase inhibitor containing at least one extract of strawberry leaf, sage, Nishikawayanagi, Senkaku grass, Misaki nohana leaf chervil leaf, chives leaf, and rhubarb extract has been used up to now. The plant is highly safe, inhibits aldose reductase, and can prevent various complications of diabetes.

フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 3/10 A61P 3/10 43/00 111 43/00 111 Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat II (reference) A61P 3/10 A61P 3/10 43/00 111 43/00 111

Claims (1)

【特許請求の範囲】 【請求項1】ストロベリーリーフ、セージ、西河柳、仙
鶴草、ミサキノハナの葉、チャービルの葉、チャイブス
の葉、大黄の1種以上の抽出物を配合したアルドースレ
ダクターゼ阻害剤
[Claim 1] An aldose reductase inhibitor containing one or more extracts of strawberry leaf, sage, Nishikawayanagi, Senkaku-hana, Misakinohana leaf, chervil leaf, chives leaf, and rhubarb.
JP2001279413A 2001-09-14 2001-09-14 Aldose reductase inhibitor Expired - Fee Related JP4818549B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001279413A JP4818549B2 (en) 2001-09-14 2001-09-14 Aldose reductase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001279413A JP4818549B2 (en) 2001-09-14 2001-09-14 Aldose reductase inhibitor

Publications (2)

Publication Number Publication Date
JP2003081849A true JP2003081849A (en) 2003-03-19
JP4818549B2 JP4818549B2 (en) 2011-11-16

Family

ID=19103607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001279413A Expired - Fee Related JP4818549B2 (en) 2001-09-14 2001-09-14 Aldose reductase inhibitor

Country Status (1)

Country Link
JP (1) JP4818549B2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006016388A (en) * 2004-06-01 2006-01-19 Taisho Pharmaceut Co Ltd alpha-GLUCOSIDASE INHIBITOR
JP2007161620A (en) * 2005-12-12 2007-06-28 Taisho Pharmaceut Co Ltd Method for producing agrimonia pilosa extract and beverage blended with the extract
CN101757059A (en) * 2009-12-30 2010-06-30 大连水产学院 Method for extracting alpha-glucosidase activity inhibitor from plants
CN103127250A (en) * 2013-03-07 2013-06-05 韩德五 Application of shuangligan granule for preparing drug for treating II-type diabetes mellitus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281323A (en) * 1985-10-04 1987-04-14 Tsumura Juntendo Inc Aldose reductase inhibitor
JP2001048766A (en) * 1999-08-02 2001-02-20 Mikimoto Pharmaceut Co Ltd Histamine liberation suppressing agent

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281323A (en) * 1985-10-04 1987-04-14 Tsumura Juntendo Inc Aldose reductase inhibitor
JP2001048766A (en) * 1999-08-02 2001-02-20 Mikimoto Pharmaceut Co Ltd Histamine liberation suppressing agent

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006016388A (en) * 2004-06-01 2006-01-19 Taisho Pharmaceut Co Ltd alpha-GLUCOSIDASE INHIBITOR
JP2007161620A (en) * 2005-12-12 2007-06-28 Taisho Pharmaceut Co Ltd Method for producing agrimonia pilosa extract and beverage blended with the extract
CN101757059A (en) * 2009-12-30 2010-06-30 大连水产学院 Method for extracting alpha-glucosidase activity inhibitor from plants
CN101757059B (en) * 2009-12-30 2014-04-02 大连水产学院 Method for extracting alpha-glucosidase activity inhibitor from plants
CN103127250A (en) * 2013-03-07 2013-06-05 韩德五 Application of shuangligan granule for preparing drug for treating II-type diabetes mellitus

Also Published As

Publication number Publication date
JP4818549B2 (en) 2011-11-16

Similar Documents

Publication Publication Date Title
Rahmatullah et al. A randomized survey of medicinal plants used by folk medicinal healers of Sylhet Division, Bangladesh
Kumar et al. Systematic pharmacognostical, phytochemical and pharmacological review on an ethno medicinal plant, Basella alba L
Kulkarni et al. Indian gooseberry (Emblica officinalis): Complete pharmacognosy review
KR20070111623A (en) Pharmaceutical composition for treating or preventing diabetic complication containing an extract of chinese herb as an effective ingredient
JP2001316239A (en) Skin care preparation
CN104306651A (en) Tibetan medicine composition with whitening and freckle removing function and application and preparation method of Tibetan medicine composition
Jalili et al. An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background
WO2009112054A1 (en) High bioavailability formulation of mangosteen and manufacturing process thereof
JP5725638B2 (en) Body heat production promoter
JPH0616530A (en) Cosmetic
KR100762448B1 (en) A herbal mixture extract comprising adenophora tripylla and food supplement comprising the same for prevention and treatment of liver disease
Poudel et al. Terminalia chebula Retz.
JP2010265252A (en) Hair-restoring agent
JP5171080B2 (en) Composition having antioxidative action
JP2002255837A (en) Aldose reductase inhibitor
JP2003081849A (en) Aldose reductase inhibitor
KR101402852B1 (en) Fermented bellflower pills and Preparation thereof
KR101987554B1 (en) Method of the sprout barley mixture tea increased content of antioxidant or active ingredient of Anti-diabetic with eliminating the unpleasant odor of sprout barley, powder of silkworm and leaves of Cudrania tricuspidata
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
JP2006213608A (en) Antidepressant and use of the same
KR20170003153A (en) A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien
JP7203394B1 (en) oral composition
KR101618215B1 (en) The pharmaceutical compositions for prevention or treatment of male infertility containing Rehmannia glutinosa Liboschitz var.purpurae Makino, Lycium chinense Miller, Aquillaria agallocha Roxburgh, Poria cocos Wolf, Panax ginseng C.A. Meyer and honey as a active ingredient
JP2015137264A (en) Muscle-enhancing agent
KR102478941B1 (en) Bioactive composition for health promotion containing arginine and octacosanol

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110830

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110831

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20170909

Year of fee payment: 6

R150 Certificate of patent or registration of utility model

Ref document number: 4818549

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees